



Update Summary

Entity name

CAPITOL HEALTH LIMITED

Announcement Type

Update to previous announcement

Date of this announcement

21/12/2022

Reason for update to a previous announcement

Extension of the issue date of 305,157 Shares to allow time for one radiologist to review the terms of the proposed issue following the acquisition of the FMIG clinics.

The remaining 610,314 will be issued effective date 20 December 2022.

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

CAPITOL HEALTH LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ACN

Registration Number

117391812

1.3 ASX issuer code

CAJ

1.4 The announcement is☒ Update/amendment to previous announcement**1.4a Reason for update to a previous announcement**

Extension of the issue date of 305,157 Shares to allow time for one radiologist to review the terms of the proposed issue following the acquisition of the FMIG clinics.

The remaining 610,314 will be issued effective date 20 December 2022.

1.4b Date of previous announcement to this update

5/12/2022

1.5 Date of this announcement

21/12/2022

1.6 The Proposed issue is:☒ A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

☒ No

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

☒ Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

☒ No

Details of +securities proposed to be issued

ASX +security code and description

CAJ : ORDINARY FULLY PAID

Number of +securities proposed to be issued

915,471

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

☒ No

Please describe the consideration being provided for the +securities

To be issued in connection with the acquisition of Future Medical Imaging Group as announced on 25 August 2022. CAJ is acquiring the FMIG clinics for a total consideration of \$56.1m pre-transaction costs, inclusive of \$6.3m paid in scrip.

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

915,471.000000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

☒ Yes



Part 7C - Timetable

7C.1 Proposed +issue date

17/2/2023

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

☒ No

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

☒ Yes

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

915,471

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

☒ No

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

☒ No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

☒ No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

☒ Yes

7D.4a Please enter the number and +class of the +securities subject to +voluntary escrow and the date from which they will cease to be subject to +voluntary escrow

915,471 Fully Paid Ordinary Shares will be under voluntary escrow and will be subject to ongoing engagement for radiologist services. 50% will be released 12 months post completion of the FMIG acquisition dated 4 November 2022 (i.e., on 3 November 2023) and 50% will be released 24 months post completion of the FMIG acquisition dated 4 November 2022 (i.e., on 4 November 2024), with both tranches also subject to ongoing engagement for radiologist services.

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

☒ No



7E.2 Is the proposed issue to be underwritten?

☒ No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

N/A

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

For the acquisition of FMIG clinics, as announced on 25 August 2022.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

☒ No

7F.2 Any other information the entity wishes to provide about the proposed issue

Extension of the issue date of 305,157 Shares to allow time for one radiologist to review the terms of the proposed issue following the acquisition of the FMIG clinics.

The remaining 610,314 will be issued effective date 20 December 2022.

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

☒ The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)